atorvastatin has been researched along with pitavastatin in 129 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 34 (26.36) | 29.6817 |
| 2010's | 82 (63.57) | 24.3611 |
| 2020's | 13 (10.08) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Barton, P; Ismair, M; Jupp, R; Riley, RJ; Soars, MG | 1 |
| Houston, JB; Jigorel, E | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Aoki, T; Kitahara, M; Saito, Y; Sato, F; Suzuki, H; Tamaki, T; Yamazaki, H | 1 |
| Hamakubo, T; Inoue, K; Kitahara, M; Kodama, T; Morikawa, S; Nakagawa, S; Saito, Y; Suganami, H; Umetani, M; Yamazaki, H | 1 |
| Hamakubo, T; Itoh, T; Izumi, A; Kanke, T; Kodama, T; Mataki, C; Morikawa, S; Saito, Y; Takabe, W; Wada, Y | 1 |
| Fujino, H; Kojima, J; Saito, T; Tsunenari, Y | 1 |
| Aoki, T; Kitahara, M; Saito, Y; Sato, F; Tamaki, T; Yamazaki, H | 1 |
| Aoki, T; Kitahara, M; Maejima, T; Saito, Y; Sato, F; Yamazaki, H | 1 |
| Fujino, H; Hirano, M; Kojima, J; Shimada, S; Tsunenari, Y; Yamada, I | 1 |
| Bernier, L; Chamberland, A; Davignon, J; Dubuc, G; Prat, A; Seidah, NG; Wassef, H | 1 |
| Hatta, T; Irie, H; Kameyama, H; Kusaba, T; Kuwahara, N; Matsubara, H; Narumiya, H; Sasaki, S; Takeda, K; Tamagaki, K | 1 |
| Hasegawa, R; Hirata-Koizumi, M; Miyake, S; Saito, M; Urano, T | 1 |
| Arii, K; Hashimoto, K; Ikeda, Y; Kumon, Y; Osaki, F; Ota, K; Suehiro, T | 1 |
| Abe, K; Deguchi, K; Hayashi, T; Nagano, I; Nagotani, S; Sato, K; Shoji, M; Zhang, W | 1 |
| Hamakubo, T; Izumi, A; Kodama, T; Morikawa, S; Murakami, T; Saito, Y; Yamazaki, H | 1 |
| Miyashita, Y; Murano, T; Oyama, T; Saiki, A; Shirai, K; Watanabe, F | 1 |
| Ando, H; Fujimura, A; Kaneko, S; Miyata, M; Sugimoto, K; Takamura, T; Tsuruoka, S; Yamazoe, Y; Yanagihara, H | 1 |
| Jadhav, SB; Jain, GK | 1 |
| Ishii, T; Kaneki, M; Miyauchi, A; Nagakura, C; Sakurai, S; Tsujibayashi, T; Yoshitomi, Y | 1 |
| Hayashi, T; Ka, Y; Kitamura, A; Matsumura, Y; Mori, T; Ohkita, M; Sugii, M; Takaoka, M | 1 |
| Daida, H; Hiro, T; Kimura, T; Matsuzaki, M; Miyauchi, K; Morimoto, T; Nakagawa, Y; Ozaki, Y; Yamagishi, M | 1 |
| Hashimoto, T; Igarashi, J; Kosaka, H; Kubota, Y; Miyoshi, M | 1 |
| Fukuda, N; Fukuda, Y; Morishita, S; Nada, T; Sakabe, K; Shinohara, H; Tamura, Y; Wakayama, K | 1 |
| Hatta, T; Hushiki, S; Irie, H; Kobara, M; Kuwahara, N; Matsubara, H; Nakata, T; Narumiya, H; Sasaki, S; Takeda, K; Tatsumi, T | 1 |
| Inazu, A; Katsuda, S; Kawashiri, MA; Kobayashi, J; Koizumi, J; Mabuchi, H; Mori, M; Nohara, A; Tada, H; Tsuchida, M; Yamagishi, M | 1 |
| Ahn, TH; Cha, KS; Choi, SW; Chung, N; Han, SW; Ho Yun, K; Hyon, MS; Kim, CJ; Kim, DI; Kim, HS; Kim, WH; Kwan, J; Lee, SH; Park, SH; Seo, HS; Shim, WJ; Shin, DG; Shin, YW; Yoon, MH | 1 |
| Bujo, H; Hanaoka, H; Kodama, T; Mikami, K; Miyashita, Y; Nishikawa, T; Saito, Y; Shinomiya, M; Tada, N; Yokote, K | 1 |
| Grime, K; Riley, RJ; Webborn, PJ | 1 |
| Hirano, T; Ito, Y; Michishita, I; Nozue, T | 1 |
| Ageta, M; Biro, S; Ikeda, Y; Kajiwara, K; Kobori, S; Kono, S; Kuribayashi, T; Otonari, T; Saikawa, T; Sasaki, J; Yamamoto, K | 1 |
| Jaggi, AS; Koladiya, RU; Sharma, BK; Singh, N | 1 |
| Kadonosono, K; Takano, T; Tanaka, S; Terauchi, Y; Yamakawa, T | 1 |
| Fukumoto, Y; Rashid, M; Seto, M; Shimokawa, H; Tawara, S; Yano, K | 1 |
| Inui, N; Kagawa, Y; Kokudai, M; Sakaeda, T; Takeuchi, K; Watanabe, H | 1 |
| Saito, Y; Yokote, K | 1 |
| Daida, H; Hiro, T; Kimura, K; Kimura, T; Matsuzaki, M; Miyauchi, K; Morimoto, T; Nakagawa, Y; Ozaki, Y; Saito, S; Yamagishi, M; Yamaguchi, T | 2 |
| Chung, RT; Moriguchi, H; Sato, C | 1 |
| Kaneda, H; Ma, J; Morita, T | 1 |
| Dhumma-Upakorn, R; Putwai, P; Sansanayudh, N; Wongwiwatthananukit, S | 1 |
| Shimano, H; Teramoto, T; Urashima, M; Yokote, K | 1 |
| Watson, KE | 1 |
| Fujimori, S; Kaneko, K; Ogata, N; Oka, Y | 1 |
| Arai, H; Daida, H; Hiro, T; Kimura, K; Kimura, T; Matsuzaki, M; Miyauchi, K; Morimoto, T; Nakagawa, Y; Ozaki, Y; Saito, S; Yamagishi, M; Yamaguchi, T | 1 |
| Daida, H; Hiro, T; Ichimiya, S; Ishii, H; Kanashiro, M; Kimura, T; Matsuzaki, M; Miyauchi, K; Morimoto, T; Murohara, T; Nakagawa, Y; Ohashi, T; Ozaki, Y; Shibata, R; Yamagishi, M | 1 |
| Akishita, M; Eto, M; Iijima, K; Kahyo, T; Kano, MR; Ogawa, S; Ota, H; Ouchi, Y; Setou, M | 1 |
| Choi, MK; Choi, YL; Deng, JW; Shin, HJ; Shin, JG; Song, IS | 1 |
| Abe, A; Katayama, Y; Katsura, K; Nagayama, H; Nishiyama, Y; Otsuka, T; Ueda, M | 1 |
| Abe, K; Ikeda, Y; Kozuki, M; Kurata, T; Matsuura, T; Miyazaki, K; Morimoto, N; Nagai, M; Ohta, Y; Panin, VL | 1 |
| Sasaki, J | 1 |
| Betteridge, J | 1 |
| Higa, M; Masuzaki, H; Shimabukuro, M; Shimabukuro, T; Tanaka, H; Yamakawa, K | 1 |
| Kadonosono, K; Kaneko, T; Kawaguchi, J; Morita, S; Shigematu, E; Terauchi, Y; Yamakawa, T | 1 |
| Abe, K; Ikeda, Y; Kozuki, M; Kurata, T; Miyazaki, K; Morimoto, N; Ohta, Y | 3 |
| Noda, K; Saku, K; Zhang, B | 2 |
| Ayaori, M; Ikewaki, K | 1 |
| Barone, E; Butterfield, DA; Mancuso, C | 1 |
| Chisaki, I; Gouda, K; Iseki, K; Itagaki, S; Kobayashi, M; Ochiai, M | 1 |
| Kongsuwan, S; Niyomrat, P; Poolsup, N; Rungkanchananon, B; Suksomboon, N; Wongyaowarat, K | 1 |
| Fujita, K; Hasuike, T; Horimatsu, T; Maruyama, T; Masuda, S; Miki, K; Nishibori, Y; Takada, M | 1 |
| Chayama, K; Inoue, M; Ishigaki, T; Ishii, Y; Itsuki, H; Kamigaki, M; Kobayashi, K; Kosaka, K; Minami, T; Okazaki, A; Sasaki, T; Serikawa, M; Yukutake, M | 1 |
| Budinski, D; Gosho, M; Gumprecht, J; Hounslow, N | 1 |
| Daida, H; Hibi, K; Hiro, T; Kimura, K; Kimura, T; Matsuzaki, M; Miyauchi, K; Morimoto, T; Nakagawa, Y; Ozaki, Y; Saito, S; Yamagishi, M; Yamaguchi, T | 1 |
| Saito, Y | 1 |
| Chapman, MJ | 1 |
| Teramoto, T | 1 |
| Nishigaki, K | 1 |
| Daida, H; Hasegawa, Y; Hirayama, A; Hiro, T; Kadota, K; Kimura, K; Kimura, T; Matsuzaki, M; Miyauchi, K; Morimoto, T; Nakagawa, Y; Ozaki, Y; Uchiyama, S; Yamagishi, M | 1 |
| Chen, Y; Duan, Y; Hajjar, DP; Han, J; He, GW; Hu, W; Jiang, M; Li, X; Yao, Z; Yin, Z; Zhou, X; Zhu, Y | 1 |
| Endo, K; Miyashita, Y; Murano, T; Ohira, M; Saiki, A; Shirai, K; Tatsuno, I; Terai, K; Watanabe, F | 1 |
| Hasebe, N; Ota, H; Takeuchi, T | 1 |
| Abe, K; Ikeda, Y; Kawai, H; Kozuki, M; Kurata, T; Miyazaki, K; Morimoto, N; Ohta, Y | 1 |
| Amano, T; Asai, K; Daida, H; Hiro, T; Kimura, T; Kosaka, T; Kuhara, Y; Kurita, A; Kuroda, Y; Maeda, K; Matsuzaki, M; Miyauchi, K; Mizuno, T; Morimoto, T; Nakagawa, Y; Ozaki, Y; Takashima, H; Yamagishi, M | 1 |
| Fujii, K; Masuyama, T | 1 |
| Daida, H; Hiro, T; Kimura, T; Matsuzaki, M; Miyauchi, K; Morimoto, T; Nakagawa, Y; Ogita, M; Ozaki, Y; Yamagishi, M | 1 |
| Furutani, N; Ikewaki, K; Ito, K; Kurata, H; Shoda, T; Tada, N; Tsimikas, S; Witztum, JL; Yanai, H; Yoshida, H | 1 |
| Ishikawa, T; Kinoshita, M; Mashimo, Y; Numakura, M; Teramoto, T | 1 |
| Araki, W; Hosaka, A; Oda, A; Tamaoka, A; Tomidokoro, Y | 1 |
| Abe, K; Ikeda, Y; Kawai, H; Kurata, T; Miyazaki, K; Morimoto, N; Ohta, Y | 1 |
| Asada, K; Chisaki, I; Gouda, K; Iseki, K; Kobayashi, M; Konishi, T; Koshida, Y; Ogura, J; Sasaki, S; Takahashi, N; Yamaguchi, H | 1 |
| Fukumoto, Y; Kudo, S; Liao, JK; Minami, T; Nochioka, K; Shiba, N; Shimokawa, H; Takai, Y; Tanaka, S; Williams, CL | 1 |
| Biwa, T; Kurogi, K; Matsui, K; Nakamura, S; Ogawa, H; Sakamoto, K; Sugiyama, S; Tayama, S | 1 |
| Chen, JW; Chen, JY; Chien, KL; Hsia, CH; Hung, YR; Lin, HJ; Lin, LY; Liu, PY; Wu, TC; Yeh, HI | 1 |
| Franzoni, F; Gaudio, C; Greco, C; Marazzi, G; Pelliccia, F; Polacco, M; Rosano, G; Speziale, G; Spoletini, I; Vitale, C | 1 |
| Kakuda, H; Matoba, M; Nagao, S; Nakatoh, H; Takekoshi, N | 1 |
| Cho, DY; Hong, JH; Hyeon, SH; Kim, CJ; Kim, EY; Kim, H; Kim, SW; Kim, TH; Kwon, JE; Lee, WS; Mintz, GS; Senguttuvan, NB; Seo, JS; Seok, JW; Weissman, NJ | 1 |
| Huang, XH; Hui, RT; Liu, G; Lu, J; Xu, YL; Zheng, XX | 1 |
| Chang, TT; Chen, JS; Chen, JW; Huang, CC; Huang, PH; Leu, HB; Lin, LY; Lin, SJ; Wu, TC | 1 |
| Hirayama, A; Nagao, K; Takahashi, A; Tani, S | 1 |
| Ahn, CW; Cha, BS; Cho, Y; Choe, E; Choi, Y; Kang, ES; Lee, HC; Lee, YH; Seo, JW; Wang, HJ; Yun, Y | 1 |
| de Entrambasaguas, M; Peñaranda, N; Ponz, A; Sánchez-Monzó, P | 1 |
| Atarashi, H; Kohashi, K; Kosugi, M; Kusama, Y; Nakagomi, A; Shibui, T; Shimizu, W | 1 |
| Nater, H; Perger, L; Suter, PM | 1 |
| Zhao, SP; Zhao, W | 1 |
| Banach, M; Blaha, MJ; Chruściel, P; Jones, SR; Lip, GY; Martin, SS; Mikhailidis, DP; Mosteoru, S; Pencina, MJ; Ray, KK; Rembek-Wieliczko, M; Rysz, J; Sahebkar, A; Serban, MC; Toth, PP; Ursoniu, S | 1 |
| Daida, H; Dohi, T | 1 |
| Bai, Y; Chan, C; Chang, X; Cheng, N; Cheng, Z; Lu, Y; Zhao, Y | 1 |
| Duan, P; Zhang, L; Zhao, P | 1 |
| Anoopkumar-Dukie, S; Davey, AK; McFarland, AJ | 1 |
| Baik, SJ; Cho, JH; Choi, IY; Jeong, YJ; Kim, H; Kim, HS; Kim, TM; Lee, H; Lee, SH; Yang, SJ; Yim, HW; Yoon, KH | 1 |
| Barton, HA; Li, R | 1 |
| Cho, GY; Jung, JH; Kim, HK; Kim, HL; Kim, YJ; Lee, SP; Park, JB; Sohn, DW; Yoon, YE | 1 |
| Amano, T; Fujiwara, H; Hibi, K; Ishii, H; Kawasaki, M; Kimura, K; Koshida, R; Kozuma, K; Miyamoto, T; Morino, Y; Morita, S; Murohara, T; Otsuji, Y; Ozaki, Y; Sata, M; Sato, K; Sonoda, S | 1 |
| An, F; Li, D; Li, X; Liu, D; Liu, H; Pan, J; Tian, J; Wang, X; Zhang, M | 1 |
| Liu, Y; Shao, Y; Tao, J; Zhang, J | 1 |
| Chae, SC; Cho, MC; Choi, BG; Choi, CU; Choi, JY; Hwang, SY; Jang, WY; Jeong, MH; Kim, CJ; Kim, DY; Kim, EJ; Kim, HS; Kim, JW; Kim, W; Kim, YJ; Lee, S; Na, JO; Park, CG; Park, EJ; Rha, SW; Seo, HS | 1 |
| Jonnalagadda, VG | 1 |
| Chan, P; Liu, ZM; Shao, L; Tomlinson, B; Zhang, Y | 1 |
| Benet, LZ; Bowman, CM; Okochi, H | 1 |
| Tao, J | 1 |
| Ito, Y; Kasahara, M; Kasama, S; Kurabayashi, M; Nakata, T; Suzuki, S; Takahashi, S; Toyama, T | 1 |
| Chiba, T; Fujioka, T; Hara, F; Iwasaki, Y; Moroi, M; Nagayama, D; Nishizawa, K; Saiki, A; Sato, N; Shiba, T; Shimizu, K; Shirai, K; Sugi, K; Sugimoto, H; Takahashi, M; Tatsuno, I; Usui, S; Yamamura, S; Yamasaki, J | 1 |
| Adams, SP; Alaeiilkhchi, N; Wright, JM | 1 |
| Kang, HT; Kim, HS; Kim, J; Lee, JW; Yang, W | 1 |
| Chen, MF; Chien, KL; Hsu, HC; Lee, YT; Lin, HJ; Lu, TP; Su, TC; Yu, SL | 1 |
| Wu, Y; Xu, Y | 1 |
| Cao, X; Chen, Y; Huang, X; Li, Y; Wu, L; Xiao, H; Zhou, X | 1 |
| Kanayama, M; Miyashita, Y; Moroi, M; Nagayama, D; Ohira, M; Saiki, A; Sato, N; Shimizu, K; Shirai, K; Takahashi, M; Tatsuno, I; Watanabe, Y; Yamaguchi, T | 1 |
| Butterton, JR; Caro, L; Fandozzi, CM; Feng, HP; Fraser, IP; Guo, Z; Iwamoto, M; Levine, V; Panebianco, D; Prueksaritanont, T; Swearingen, D; Wolford, D; Yeh, WW | 1 |
| Kobayashi, J | 1 |
| Jin, ES; Kim, J; Kim, KJ; Kim, SE; Kim, Y; Park, M; Park, RW; Park, YM; Rhee, SY; Seo, SI; Seo, WW; Shin, WG; Yoo, JJ; You, SC | 1 |
| Alkaabi, M; Amoodi, AA; Baraka, MA; Don, J; Elnour, AA; Farah, FH; Mazrouei, NA; Ramadan, A; Sadeq, A; Sam, KG | 1 |
| Alaylioglu, M; Dogan, AS; Dursun, E; Gezen-Ak, D; Onal, B; Ugurlucan, M; Yenmis, G | 1 |
20 review(s) available for atorvastatin and pitavastatin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Statins and osteoporosis: new role for old drugs.
Topics: Animals; Atorvastatin; Bone and Bones; Clinical Trials as Topic; Drug Delivery Systems; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Fractures, Bone; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver; Lovastatin; Osteogenesis; Osteoporosis; Pharmacokinetics; Pravastatin; Pyridines; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
New evidence on pitavastatin: efficacy and safety in clinical studies.
Topics: Animals; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Practice Guidelines as Topic; Pyrroles; Quinolines | 2010 |
Pitavastatin approved for treatment of primary hypercholesterolemia and combined dyslipidemia.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase III as Topic; Dyslipidemias; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Quinolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2010 |
Pitavastatin - results from phase III & IV.
Topics: Atorvastatin; Clinical Trials, Phase III as Topic; Clinical Trials, Phase IV as Topic; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrroles; Quinolines; Simvastatin | 2010 |
Meta-analysis of the comparative efficacy and safety of pitavastatin and atorvastatin in patients with dyslipidaemia.
Topics: Anticholesteremic Agents; Atorvastatin; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Pyrroles; Quinolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2012 |
Pitavastatin: an overview.
Topics: Antioxidants; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase IV as Topic; Endothelium, Vascular; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Japan; Metabolic Syndrome; Molecular Structure; Multicenter Studies as Topic; Plaque, Atherosclerotic; Pyrroles; Quinolines; Receptors, LDL | 2011 |
Pitavastatin: novel effects on lipid parameters.
Topics: Apolipoprotein A-I; Apolipoproteins B; Atherosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase III as Topic; Clinical Trials, Phase IV as Topic; Coronary Artery Disease; Double-Blind Method; Dyslipidemias; Europe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Lipids; Multicenter Studies as Topic; Plaque, Atherosclerotic; Pyrroles; Quinolines; Randomized Controlled Trials as Topic; Russia; Simvastatin; Triglycerides | 2011 |
Pitavastatin: clinical effects from the LIVES Study.
Topics: Atorvastatin; Biomarkers; Cardiovascular Diseases; Cerebrovascular Disorders; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase IV as Topic; Comorbidity; Diabetes Mellitus, Type 2; Dyslipidemias; Glomerular Filtration Rate; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Kidney Diseases; Multicenter Studies as Topic; Muscular Diseases; Prospective Studies; Pyrroles; Quinolines; Risk; Simvastatin; Treatment Outcome; Triglycerides | 2011 |
[Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome (JAPAN-aCS) study].
Topics: Acute Coronary Syndrome; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Plaque, Atherosclerotic; Pyrroles; Quinolines | 2011 |
Effects of lipophilic statins for heart failure: a meta-analysis of 13 randomised controlled trials.
Topics: Atorvastatin; Cholesterol, LDL; Disease Progression; Heart Failure; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Quinolines; Randomized Controlled Trials as Topic; Simvastatin; Stroke Volume; Ventricular Dysfunction, Left | 2014 |
[Help me--I do not tolerate my statin].
Topics: Aged; Aged, 80 and over; Atorvastatin; Diagnosis, Differential; Drug Substitution; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myalgia; Patient Education as Topic; Pyrroles; Quinolines; Risk Factors; Ubiquinone | 2015 |
Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms.
Topics: Adiponectin; Adult; Aged; Atorvastatin; Cardiovascular Diseases; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Quinolines; Randomized Controlled Trials as Topic; Regression Analysis; Rosuvastatin Calcium; Simvastatin | 2016 |
Efficacy and safety of long-term treatment with statins for coronary heart disease: A Bayesian network meta-analysis.
Topics: Anticholesteremic Agents; Atorvastatin; Bayes Theorem; Coronary Disease; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Kidney Diseases; Lipids; Lovastatin; Muscles; Network Meta-Analysis; Patient Safety; Pravastatin; Quinolines; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2016 |
Effect of pitavastatin and atorvastatin on regression of atherosclerosis assessed using intravascular ultrasound: a meta-analysis.
Topics: Aged; Atorvastatin; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Dyslipidemias; Female; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Plaque, Atherosclerotic; Predictive Value of Tests; Quinolines; Randomized Controlled Trials as Topic; Remission Induction; Treatment Outcome; Ultrasonography, Interventional | 2018 |
An evaluation of pitavastatin for the treatment of hypercholesterolemia.
Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Quinolines; Treatment Outcome | 2019 |
Pitavastatin for lowering lipids.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Controlled Before-After Studies; Drug Administration Schedule; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Pyridines; Quinolines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sex Factors; Triglycerides | 2020 |
Atorvastatin associated with gamma glutamyl transpeptidase elevation in a hyperlipidemia patient: A case report and literature review.
Topics: Alanine Transaminase; Alkaline Phosphatase; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; gamma-Glutamyltransferase; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Quinolines; Withholding Treatment | 2020 |
Impact of pitavastatin on new-onset diabetes mellitus compared to atorvastatin and rosuvastatin: a distributed network analysis of 10 real-world databases.
Topics: Atorvastatin; Cohort Studies; Diabetes Mellitus; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Multicenter Studies as Topic; Quinolines; Retrospective Studies; Rosuvastatin Calcium | 2022 |
A Systematic Review of Randomized Clinical Trials on the Efficacy and Safety of Pitavastatin.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Metabolic Syndrome; Pravastatin; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin | 2023 |
44 trial(s) available for atorvastatin and pitavastatin
| Article | Year |
|---|---|
Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin.
Topics: Adult; Anticholesteremic Agents; Area Under Curve; Atorvastatin; Beverages; Citrus paradisi; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Food-Drug Interactions; Heptanoic Acids; Humans; Male; Pyrroles; Quinolines | 2005 |
Efficacy of a low dose of pitavastatin compared with atorvastatin in primary hyperlipidemia: results of a 12-week, open label study.
Topics: Aged; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Quinolines; Safety; Triglycerides | 2006 |
Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS): rationale and design.
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Myocardial Ischemia; Pyrroles; Quinolines; Research Design; Syndrome | 2006 |
Comparisons of short- and intermediate-term effects of pitavastatin versus atorvastatin on lipid profiles, fibrinolytic parameter, and endothelial function.
Topics: Aged; Atorvastatin; Coronary Artery Disease; Endothelium, Vascular; Female; Fibrinolysis; Heptanoic Acids; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Male; Middle Aged; Prospective Studies; Pyrroles; Quinolines; Time Factors; Vasodilation | 2008 |
Comparison of effects of pitavastatin and atorvastatin on plasma coenzyme Q10 in heterozygous familial hypercholesterolemia: results from a crossover study.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Coenzymes; Cross-Over Studies; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Quinolines; Triglycerides; Ubiquinone | 2008 |
Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
Topics: Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Korea; Male; Middle Aged; Pyrroles; Quinolines; Triglycerides | 2007 |
Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis preventi
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Body Mass Index; Body Weight; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Japan; Male; Middle Aged; Pyrroles; Quinolines; Waist Circumference | 2008 |
Effects of statin on small dense low-density lipoprotein cholesterol and remnant-like particle cholesterol in heterozygous familial hypercholesterolemia.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Female; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins; Male; Middle Aged; Models, Biological; Pyrroles; Quinolines; Regression Analysis; Triglycerides | 2008 |
A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density li
Topics: Anticholesteremic Agents; Atorvastatin; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Enzyme Inhibitors; Female; Follow-Up Studies; Glucose Intolerance; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hypercholesterolemia; Japan; Male; Middle Aged; Pyrroles; Quinolines; Time Factors; Treatment Outcome | 2008 |
Importance of Rac1 signaling pathway inhibition in the pleiotropic effects of HMG-CoA reductase inhibitors.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Angiotensin II; Animals; Atorvastatin; Cells, Cultured; Cross-Over Studies; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertrophy, Left Ventricular; Leukocytes; Male; Pravastatin; Pyrroles; Quinolines; rac1 GTP-Binding Protein; ras Proteins; Rats; Rats, Inbred WKY; rho-Associated Kinases; rhoA GTP-Binding Protein; Signal Transduction | 2009 |
Effects of statins on the pharmacokinetics of midazolam in healthy volunteers.
Topics: Adult; Area Under Curve; Atorvastatin; Cross-Over Studies; Cytochrome P-450 CYP3A; Drug Interactions; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypnotics and Sedatives; Japan; Male; Midazolam; Pyrroles; Quinolines; Simvastatin | 2009 |
Influence of statins on glucose tolerance in patients with type 2 diabetes mellitus: subanalysis of the collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study).
Topics: Atherosclerosis; Atorvastatin; Diabetes Mellitus, Type 2; Glucose Intolerance; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles; Quinolines; Treatment Outcome | 2009 |
Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Coronary Artery Disease; Coronary Vessels; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Quinolines; Treatment Outcome; Ultrasonography, Interventional | 2009 |
Comparative efficacy and safety of low-dose pitavastatin versus atorvastatin in patients with hypercholesterolemia.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cholesterol; Cholesterol, LDL; Cost-Benefit Analysis; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrroles; Quinolines; Treatment Outcome | 2010 |
Diabetes mellitus is a major negative determinant of coronary plaque regression during statin therapy in patients with acute coronary syndrome--serial intravascular ultrasound observations from the Japan Assessment of Pitavastatin and Atorvastatin in Acut
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Coronary Artery Disease; Diabetes Mellitus; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Quinolines; Treatment Outcome; Ultrasonography, Interventional | 2010 |
Effects of three strong statins (atorvastatin, pitavastatin, and rosuvastatin) on serum uric acid levels in dyslipidemic patients.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dyslipidemias; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Sulfonamides; Uric Acid | 2010 |
More intensive lipid lowering is associated with regression of coronary atherosclerosis in diabetic patients with acute coronary syndrome--sub-analysis of JAPAN-ACS study.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Diabetes Complications; Diabetes Mellitus; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Male; Middle Aged; Prospective Studies; Pyrroles; Quinolines; Treatment Outcome; Ultrasonography, Interventional | 2010 |
Correlation between circulating adiponectin levels and coronary plaque regression during aggressive lipid-lowering therapy in patients with acute coronary syndrome: subgroup analysis of JAPAN-ACS study.
Topics: Acute Coronary Syndrome; Adiponectin; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Coronary Vessels; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Logistic Models; Male; Middle Aged; Odds Ratio; Prospective Studies; Pyrroles; Quinolines; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Triglycerides; Ultrasonography, Interventional; Up-Regulation | 2010 |
Statin treatment decreased serum asymmetric dimethylarginine (ADMA) levels in ischemic stroke patients.
Topics: Aged; Aged, 80 and over; Arginine; Atherosclerosis; Atorvastatin; Brain Ischemia; Cholesterol, LDL; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Linear Models; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Quinolines; Stroke | 2011 |
Distinct effects of pitavastatin and atorvastatin on lipoprotein subclasses in patients with Type 2 diabetes mellitus.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins; Male; Middle Aged; Pyrroles; Quinolines; Treatment Outcome | 2011 |
Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial.
Topics: Aged; Analysis of Variance; Atorvastatin; Biomarkers; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Japan; Male; Middle Aged; Patient Selection; Prospective Studies; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome | 2011 |
Comparison of preventive effect on cardiovascular events with different statins. -The CIRCLE study-.
Topics: Aged; Aged, 80 and over; Angioplasty; Asian People; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Male; Middle Aged; Postoperative Complications; Pyrroles; Quinolines; Retrospective Studies; Risk Factors | 2011 |
Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Quinolines; Treatment Outcome; Young Adult | 2011 |
Clinically evident polyvascular disease and regression of coronary atherosclerosis after intensive statin therapy in patients with acute coronary syndrome: serial intravascular ultrasound from the Japanese assessment of pitavastatin and atorvastatin in ac
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Atherosclerosis; Atorvastatin; Chi-Square Distribution; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Prospective Studies; Pyrroles; Quinolines; Regression Analysis; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2011 |
[Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): -- the PATROL trial].
Topics: Atorvastatin; Cholesterol, LDL; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Sulfonamides | 2011 |
[Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome (JAPAN-aCS) study].
Topics: Acute Coronary Syndrome; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Plaque, Atherosclerotic; Pyrroles; Quinolines | 2011 |
Clustering of metabolic syndrome components attenuates coronary plaque regression during intensive statin therapy in patients with acute coronary syndrome: the JAPAN-ACS subanalysis study.
Topics: Acute Coronary Syndrome; Aged; Analysis of Variance; Atorvastatin; Biomarkers; Body Mass Index; Chi-Square Distribution; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Coronary Vessels; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Linear Models; Male; Metabolic Syndrome; Middle Aged; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Prospective Studies; Pyrroles; Quinolines; Time Factors; Treatment Outcome; Triglycerides; Ultrasonography, Interventional | 2012 |
Effects of pitavastatin and atorvastatin on lipoprotein oxidation biomarkers in patients with dyslipidemia.
Topics: Atorvastatin; Biomarkers; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins; Male; Middle Aged; Oxidation-Reduction; Prospective Studies; Pyrroles; Quinolines | 2013 |
Statins exert the pleiotropic effects through small GTP-binding protein dissociation stimulator upregulation with a resultant Rac1 degradation.
Topics: Adaptor Proteins, Signal Transducing; Angiotensin II; Animals; Atorvastatin; Biomarkers; Cardiomegaly; Cells, Cultured; Cholesterol; Cholesterol, LDL; Coronary Vessels; Cross-Over Studies; Cytoskeletal Proteins; Disease Models, Animal; Dose-Response Relationship, Drug; Fibrosis; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Guanine Nucleotide Exchange Factors; Heptanoic Acids; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Male; Mice; Mice, Knockout; Neuropeptides; Oxidative Stress; Phosphatidylinositol 3-Kinase; Pravastatin; Proto-Oncogene Proteins c-akt; Pyrroles; Quinolines; rac GTP-Binding Proteins; rac1 GTP-Binding Protein; RNA Interference; Signal Transduction; Transfection | 2013 |
Comparison of pitavastatin with atorvastatin in increasing HDL-cholesterol and adiponectin in patients with dyslipidemia and coronary artery disease: the COMPACT-CAD study.
Topics: Adiponectin; Adult; Aged; Aged, 80 and over; Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Coronary Artery Disease; Endpoint Determination; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Quinolines; Young Adult | 2013 |
Pitavastatin and Atorvastatin double-blind randomized comPArative study among hiGh-risk patients, including thOse with Type 2 diabetes mellitus, in Taiwan (PAPAGO-T Study).
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Lipoproteins; Male; Middle Aged; Pyrroles; Quinolines; Risk Factors; Treatment Outcome; Triglycerides | 2013 |
Pharmacodynamic comparison of pitavastatin versus atorvastatin on platelet reactivity in patients with coronary artery disease treated with dual antiplatelet therapy.
Topics: Aged; Aged, 80 and over; Aspirin; Atorvastatin; Clopidogrel; Coronary Artery Disease; Cross-Sectional Studies; Cytochrome P-450 CYP3A; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyrroles; Quinolines; Ticlopidine | 2014 |
Comparison of atorvastatin, pitavastatin and rosuvastatin for residual cardiovascular risk using non-fasting blood sampling.
Topics: Aged; Aged, 80 and over; Apolipoprotein A-I; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoprotein Lipase; Male; Middle Aged; Pyrimidines; Pyrroles; Quinolines; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2014 |
Effects of pitavastatin versus atorvastatin on the peripheral endothelial progenitor cells and vascular endothelial growth factor in high-risk patients: a pilot prospective, double-blind, randomized study.
Topics: Aged; Atorvastatin; Biomarkers; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelial Progenitor Cells; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pilot Projects; Prospective Studies; Pyrroles; Quinolines; Risk Factors; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
Contribution of apolipoprotein A-I to the reduction in high-sensitivity C-reactive protein levels by different statins: comparative study of pitavastatin and atorvastatin.
Topics: Aged; Anticholesteremic Agents; Apolipoprotein A-I; Atorvastatin; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Japan; Male; Middle Aged; Prospective Studies; Quinolines; Regression Analysis | 2015 |
Differential Effects of Atorvastatin and Pitavastatin on Inflammation, Insulin Resistance, and the Carotid Intima-Media Thickness in Patients with Dyslipidemia.
Topics: Aged; Atorvastatin; Carotid Artery Diseases; Carotid Intima-Media Thickness; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Insulin Resistance; Male; Prognosis; Prospective Studies; Quinolines | 2015 |
Long-term Effects of high-doSe pitavaStatin on Diabetogenicity in comparison with atorvastatin in patients with Metabolic syndrome (LESS-DM): study protocol for a randomized controlled trial.
Topics: Atorvastatin; Biomarkers; Blood Glucose; C-Peptide; Cardiovascular Diseases; Clinical Protocols; Diabetes Mellitus; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Metabolic Syndrome; Prospective Studies; Quinolines; Republic of Korea; Research Design; Risk Factors; Time Factors; Treatment Outcome | 2017 |
Effects of Ezetimibe-Statin Combination Therapy on Coronary Atherosclerosis in Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Cholesterol, LDL; Disease Progression; Drug Therapy, Combination; Ezetimibe; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Quinolines; Ultrasonography, Interventional | 2018 |
A Multi-Center, Open-Label, Two-Arm Parallel Group Non-inferiority Randomized Controlled Trial Evaluating the Effect of Pitavastatin, Compared to Atorvastatin, on Glucose Metabolism in Prediabetics with Hypertension and Dyslipidemia: Rationale and Design
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Atorvastatin; Biomarkers; Blood Glucose; Blood Pressure; China; Dyslipidemias; Equivalence Trials as Topic; Female; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Multicenter Studies as Topic; Prediabetic State; Prospective Studies; Quinolines; Time Factors; Treatment Outcome; Young Adult | 2018 |
Outcome of pitavastatin versus atorvastatin therapy in patients with hypercholesterolemia at high risk for atherosclerotic cardiovascular disease.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Pyrroles; Quinolines; Treatment Outcome | 2020 |
Statin-induced microRNAome alterations modulating inflammation pathways of peripheral blood mononuclear cells in patients with hypercholesterolemia.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Female; Gene Expression Profiling; Gene Expression Regulation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Leukocytes, Mononuclear; Male; MicroRNAs; Middle Aged; Plaque, Atherosclerotic; Quinolines; Taiwan | 2020 |
Forty-eight weeks of statin therapy for type 2 diabetes mellitus patients with lower extremity atherosclerotic disease: Comparison of the effects of pitavastatin and atorvastatin on lower femoral total plaque areas.
Topics: Aged; Atherosclerosis; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Femur; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lower Extremity; Male; Middle Aged; Plaque, Atherosclerotic; Quinolines; Treatment Outcome | 2021 |
CAVI-Lowering Effect of Pitavastatin May Be Involved in the Prevention of Cardiovascular Disease: Subgroup Analysis of the TOHO-LIP.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cardio Ankle Vascular Index; Cardiovascular Diseases; Cholesterol, LDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Quinolines | 2021 |
Evaluation of Pharmacokinetic Drug Interactions of the Direct-Acting Antiviral Agents Elbasvir and Grazoprevir with Pitavastatin, Rosuvastatin, Pravastatin, and Atorvastatin in Healthy Adults.
Topics: Adolescent; Adult; Amides; Antiviral Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily G, Member 2; Benzofurans; Carbamates; Cyclopropanes; Drug Interactions; Female; Humans; Imidazoles; Male; Middle Aged; Neoplasm Proteins; Pravastatin; Quinolines; Quinoxalines; Rosuvastatin Calcium; Sulfonamides; Young Adult | 2021 |
66 other study(ies) available for atorvastatin and pitavastatin
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
The development, characterization, and application of an OATP1B1 inhibition assay in drug discovery.
Topics: Cell Line; Drug Discovery; Humans; Liver-Specific Organic Anion Transporter 1; Organic Anion Transporters | 2012 |
Utility of drug depletion-time profiles in isolated hepatocytes for accessing hepatic uptake clearance: identifying rate-limiting steps and role of passive processes.
Topics: Animals; Hepatocytes; Male; Pharmacokinetics; Rats; Rats, Sprague-Dawley | 2012 |
Cholesterol-lowering effect of NK-104, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, in guinea pig model of hyperlipidemia.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Diet; Guinea Pigs; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hyperlipidemias; Lauric Acids; Lipids; Lipoproteins, LDL; Liver; Male; Pyrroles; Quinolines; Triglycerides | 2001 |
Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells.
Topics: Atorvastatin; Cell Line; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Lovastatin; Pravastatin; Pyrroles; Quinolines; Receptors, LDL; RNA, Messenger; Simvastatin | 2000 |
The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. Human umbilical vein endothelial cells.
Topics: Atorvastatin; Blood Coagulation; Cells, Cultured; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Oligonucleotide Array Sequence Analysis; Pyrroles; Quinolines; Receptors, LDL; RNA, Messenger; Vasoconstriction | 2002 |
Interaction between several medicines and statins.
Topics: Acids; Anticholesteremic Agents; Atorvastatin; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Indicators and Reagents; Lactones; Microsomes, Liver; Pyrroles; Quinolines | 2003 |
Triglyceride-lowering effect of pitavastatin in a guinea pig model of postprandial lipemia.
Topics: Animals; Anticoagulants; Atorvastatin; Carrier Proteins; Guinea Pigs; Heparin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Intestinal Mucosa; Lipids; Lipoproteins; Male; Postprandial Period; Pyrroles; Quinolines; Simvastatin; Triglycerides | 2003 |
Effect of pitavastatin on sterol and bile acid excretion in guinea pigs.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Bile Acids and Salts; Cholesterol 7-alpha-Hydroxylase; Cholesterol, HDL; Feces; Guinea Pigs; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Quinolines; RNA, Messenger; Simvastatin; Sterols | 2003 |
Interaction between fibrates and statins--metabolic interactions with gemfibrozil.
Topics: Atorvastatin; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Microsomes, Liver; Pyridines; Pyrroles; Quinolines | 2003 |
Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia.
Topics: Alitretinoin; Animals; Atorvastatin; Base Sequence; Cell Line; Cholesterol; Consensus Sequence; DNA-Binding Proteins; Gene Expression Regulation; Hepatocytes; Heptanoic Acids; Homeostasis; Humans; Hydroxycholesterols; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver X Receptors; Lovastatin; Mevalonic Acid; Mice; Orphan Nuclear Receptors; Promoter Regions, Genetic; Proprotein Convertase 9; Proprotein Convertases; Pyridines; Pyrroles; Quinolines; Rats; Receptors, Cytoplasmic and Nuclear; Regulatory Sequences, Nucleic Acid; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sequence Alignment; Sequence Homology, Nucleic Acid; Serine Endopeptidases; Simvastatin; Sp1 Transcription Factor; Species Specificity; Sterol Regulatory Element Binding Protein 2; Transcription Factors; Tretinoin | 2004 |
HMG-CoA reductase inhibitors up-regulate anti-aging klotho mRNA via RhoA inactivation in IMCD3 cells.
Topics: Amides; Analysis of Variance; Angiotensin II; Atorvastatin; Cell Line; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; Gene Expression Regulation; Glucuronidase; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Tubules; Klotho Proteins; Membrane Proteins; Pyridines; Pyrroles; Quinolines; Reverse Transcriptase Polymerase Chain Reaction; rhoA GTP-Binding Protein; RNA, Messenger | 2004 |
A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan.
Topics: Area Under Curve; Atorvastatin; Biomedical Research; Databases, Bibliographic; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Japan; Pharmacology, Clinical; Pravastatin; Product Labeling; Pyrroles; Quinolines; Simvastatin; United States; United States Food and Drug Administration | 2005 |
Effect of pitavastatin on transactivation of human serum paraoxonase 1 gene.
Topics: Alkyl and Aryl Transferases; Aryldialkylphosphatase; Atorvastatin; Cell Line; Cell Nucleus; DNA; Dose-Response Relationship, Drug; Electrophoretic Mobility Shift Assay; Farnesyltranstransferase; Gene Expression Regulation, Enzymologic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Luciferases; Mevalonic Acid; Plasmids; Polyisoprenyl Phosphates; Pyrroles; Quinolines; Sesquiterpenes; Sp1 Transcription Factor; Time Factors; Transcriptional Activation; Transfection | 2005 |
Reduction of cerebral infarction in stroke-prone spontaneously hypertensive rats by statins associated with amelioration of oxidative stress.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aldehydes; Animals; Atorvastatin; Blood Pressure; Body Weight; Deoxyguanosine; Disease Models, Animal; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Infarction, Middle Cerebral Artery; Lipids; Lysine; Oxidative Stress; Pyrroles; Quinolines; Rats; Rats, Inbred SHR; Simvastatin; Survival Analysis | 2005 |
Analysis of the global RNA expression profiles of skeletal muscle cells treated with statins.
Topics: Animals; Atorvastatin; Cell Culture Techniques; Cholesterol; Gene Expression Profiling; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscle Fibers, Skeletal; Myoblasts, Skeletal; Pyridines; Pyrroles; Quinolines; Rats; RNA, Messenger | 2005 |
Pitavastatin enhanced lipoprotein lipase expression in 3T3-L1 preadipocytes.
Topics: 3T3-L1 Cells; Animals; Atorvastatin; Cell Culture Techniques; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoprotein Lipase; Mevalonic Acid; Mice; Pioglitazone; PPAR gamma; Pravastatin; Pyrroles; Quinolines; RNA, Messenger; Simvastatin; Thiazolidinediones | 2005 |
Differential effects of different statins on endothelin-1 gene expression and endothelial NOS phosphorylation in porcine aortic endothelial cells.
Topics: Animals; Aorta; Atorvastatin; Cells, Cultured; Endothelial Cells; Endothelin-1; Endothelium, Vascular; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Nitric Oxide Synthase Type III; Phosphorylation; Pravastatin; Pyridines; Pyrroles; Quinolines; RNA, Messenger; Swine | 2006 |
Statins induce S1P1 receptors and enhance endothelial nitric oxide production in response to high-density lipoproteins.
Topics: Alkyl and Aryl Transferases; Animals; Atorvastatin; Blotting, Western; Cattle; Dose-Response Relationship, Drug; Endothelium, Vascular; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, HDL; Lysophospholipids; Mevalonic Acid; Nitric Oxide; Nitric Oxide Synthase Type III; Phosphorylation; Pyrroles; Quinolines; Receptors, Lysosphingolipid; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Sphingosine; Stimulation, Chemical | 2007 |
HMG-CoA reductase inhibition improves anti-aging klotho protein expression and arteriosclerosis in rats with chronic inhibition of nitric oxide synthesis.
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Glucuronidase; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Klotho Proteins; Male; Nitric Oxide Synthase; Pyrroles; Quinolines; Rats; Rats, Wistar | 2008 |
Functional consequences of active hepatic uptake on cytochrome P450 inhibition in rat and human hepatocytes.
Topics: Animals; Atorvastatin; Cells, Cultured; Culture Media; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Diclofenac; Enzyme Inhibitors; Estrone; Hepatocytes; Heptanoic Acids; Humans; Hydroxylation; Liver; Midazolam; Pyrroles; Quinolines; Rats; Recombinant Proteins; Tritium | 2008 |
Ameliorative role of Atorvastatin and Pitavastatin in L-Methionine induced vascular dementia in rats.
Topics: Animals; Anticholesteremic Agents; Aorta, Thoracic; Atorvastatin; Dementia, Vascular; Endothelium, Vascular; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Maze Learning; Memory; Methionine; Pyrroles; Quinolines; Rats; Rats, Wistar | 2008 |
Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus.
Topics: Atorvastatin; Blood Glucose; Diabetes Mellitus, Type 2; Drug Evaluation; Glucose Intolerance; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrroles; Quinolines; Retrospective Studies | 2008 |
New translational research on novel drugs for hepatitis C virus 1b infection by using a replicon system and human induced pluripotent stem cells.
Topics: Antiviral Agents; Atorvastatin; Hepacivirus; Hepatitis C; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Induced Pluripotent Stem Cells; Pyrroles; Quinolines | 2010 |
Noninferiority of pitavastatin in intravascular ultrasound findings.
Topics: Acute Coronary Syndrome; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Quinolines; Reproducibility of Results; Treatment Outcome; Ultrasonography, Interventional | 2010 |
Pitavastatin: the newest HMG-CoA reductase inhibitor.
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Product Surveillance, Postmarketing; Pyrroles; Quinolines; Simvastatin | 2010 |
Induction of endothelial nitric oxide synthase, SIRT1, and catalase by statins inhibits endothelial senescence through the Akt pathway.
Topics: Animals; Atorvastatin; Catalase; Cellular Senescence; Endothelial Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Nitric Oxide Synthase Type III; Oxidative Stress; Pravastatin; Proto-Oncogene Proteins c-akt; Pyrroles; Quinolines; Sirtuin 1; Umbilical Veins | 2010 |
Differential effect of genetic variants of Na(+)-taurocholate co-transporting polypeptide (NTCP) and organic anion-transporting polypeptide 1B1 (OATP1B1) on the uptake of HMG-CoA reductase inhibitors.
Topics: Animals; Atorvastatin; Estrone; Fluorobenzenes; Genetic Variation; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Oocytes; Organic Anion Transporters; Organic Anion Transporters, Sodium-Dependent; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Sulfonamides; Symporters; Taurocholic Acid; Xenopus laevis | 2011 |
Atorvastatin and pitavastatin improve cognitive function and reduce senile plaque and phosphorylated tau in aged APP mice.
Topics: Aging; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Atorvastatin; Body Weight; Brain; Cognition Disorders; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Maze Learning; Mice; Mice, Transgenic; Neuroprotective Agents; Organ Size; Phosphorylation; Plaque, Amyloid; Protein Processing, Post-Translational; Pyrroles; Quinolines; tau Proteins | 2011 |
Glucose-lowering effect of colestimide is associated with baseline HbA1c in type 2 diabetic patients with hypercholesterolemia.
Topics: Aged; Atorvastatin; Blood Glucose; Comorbidity; Diabetes Mellitus, Type 2; Epichlorohydrin; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hypercholesterolemia; Hypoglycemic Agents; Imidazoles; Lipids; Male; Middle Aged; Multivariate Analysis; Pravastatin; Pyrroles; Quinolines; Resins, Synthetic; Retrospective Studies; Treatment Outcome | 2011 |
Atorvastatin and pitavastatin protect cerebellar Purkinje cells in AD model mice and preserve the cytokines MCP-1 and TNF-α.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Atorvastatin; Chemokine CCL2; Disease Models, Animal; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Mice; Mice, Transgenic; Purkinje Cells; Pyrroles; Quinolines; Tumor Necrosis Factor-alpha | 2011 |
Strong statins as the major players for dyslipidemia in high-risk patients: are they all the same or not?
Topics: Analysis of Variance; Atorvastatin; Biomarkers; Cholesterol, LDL; Evidence-Based Medicine; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Patient Selection; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome | 2011 |
Cholesterol-independent neuroprotective and neurotoxic activities of statins: perspectives for statin use in Alzheimer disease and other age-related neurodegenerative disorders.
Topics: Alzheimer Disease; Animals; Atorvastatin; Cholesterol; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Neurodegenerative Diseases; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Sulfonamides | 2011 |
Regulation mechanism of ABCA1 expression by statins in hepatocytes.
Topics: Animals; Atorvastatin; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Gene Expression Regulation; Hep G2 Cells; Hepatocytes; Heptanoic Acids; Humans; Male; PPAR alpha; Pyrroles; Quinolines; Rats; Rats, Wistar | 2011 |
Statins induce apoptosis and inhibit proliferation in cholangiocarcinoma cells.
Topics: Apoptosis; Atorvastatin; Caspase 3; Cell Cycle; Cell Differentiation; Cell Growth Processes; Cell Line, Tumor; Cholangiocarcinoma; Extracellular Signal-Regulated MAP Kinases; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Neoplastic Stem Cells; Pyrroles; Quinolines | 2011 |
Progressive neurovascular disturbances in the cerebral cortex of Alzheimer's disease-model mice: protection by atorvastatin and pitavastatin.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Atorvastatin; Blotting, Western; Cerebral Cortex; Cerebrovascular Circulation; Disease Models, Animal; Endothelium, Vascular; Enzyme Activation; Female; Fluorescent Antibody Technique; Heptanoic Acids; Humans; Immunohistochemistry; Matrix Metalloproteinase 9; Mice; Mice, Transgenic; Neuroprotective Agents; Pyrroles; Quinolines | 2011 |
Qualitative plaque stabilization but not quantitative plaque regression.
Topics: Acute Coronary Syndrome; Atorvastatin; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Plaque, Atherosclerotic; Pyrroles; Quinolines | 2012 |
Reverse vessel remodeling but not coronary plaque regression could predict future cardiovascular events in ACS patients with intensive statin therapy--the extended JAPAN-ACS study.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Atorvastatin; Biomarkers; Cerebral Infarction; Cholesterol, HDL; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Plaque, Atherosclerotic; Predictive Value of Tests; Proportional Hazards Models; Pyrroles; Quinolines; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2012 |
Statins synergize dexamethasone-induced adipocyte fatty acid binding protein expression in macrophages.
Topics: Active Transport, Cell Nucleus; Adipose Tissue; Animals; Atorvastatin; Cell Line; Cholesterol; Dexamethasone; Dose-Response Relationship, Drug; Drug Synergism; Fatty Acid-Binding Proteins; Glucocorticoids; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages; Male; Mevalonic Acid; Mice; Mice, Inbred C57BL; Promoter Regions, Genetic; Protein Prenylation; Pyrroles; Quinolines; Receptors, Glucocorticoid; Time Factors; Transfection; Up-Regulation | 2012 |
Atorvastatin and pitavastatin enhance lipoprotein lipase production in L6 skeletal muscle cells through activation of adenosine monophosphate-activated protein kinase.
Topics: AMP-Activated Protein Kinases; Animals; Atorvastatin; Cells, Cultured; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoprotein Lipase; Mevalonic Acid; Muscle, Skeletal; Pyrroles; Quinolines; Rats; Real-Time Polymerase Chain Reaction; RNA, Messenger | 2012 |
Atorvastatin and pitavastatin reduce senile plaques and inflammatory responses in a mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Atorvastatin; Brain; Disease Models, Animal; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Inflammation; Mice; Mice, Transgenic; Plaque, Amyloid; Pyrroles; Quinolines | 2012 |
Statins have therapeutic potential for the treatment of Alzheimer's disease, likely via protection of the neurovascular unit in the AD brain.
Topics: Age Factors; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Analysis of Variance; Animals; Anticholesteremic Agents; Atorvastatin; Cholesterol; Collagen Type IV; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Glial Fibrillary Acidic Protein; Glucosamine; Heptanoic Acids; Humans; Matrix Metalloproteinase 9; Maze Learning; Methylcellulose; Mice; Mice, Transgenic; Mutation; Pyrroles; Quinolines | 2012 |
Who benefits from statins? Patient or focal plaque?
Topics: Acute Coronary Syndrome; Atorvastatin; Coronary Artery Disease; Coronary Vessels; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Pyrroles; Quinolines | 2012 |
Association between circulating matrix metalloproteinase levels and coronary plaque regression after acute coronary syndrome--subanalysis of the JAPAN-ACS study.
Topics: Acute Coronary Syndrome; Atorvastatin; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Matrix Metalloproteinases; Middle Aged; Plaque, Atherosclerotic; Prospective Studies; Pyrroles; Quinolines; Remission Induction | 2013 |
Critical promoter region for statin-induced human endothelial nitric oxide synthase (eNOS) transcription in EA.hy926 cells.
Topics: Atorvastatin; Cells, Cultured; Fatty Acids, Monounsaturated; Fluvastatin; Genes, Reporter; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Nitric Oxide Synthase Type III; Plasmids; Promoter Regions, Genetic; Pyrroles; Quinolines; RNA, Messenger; Transcription, Genetic | 2013 |
Statins reduce amyloid β-peptide production by modulating amyloid precursor protein maturation and phosphorylation through a cholesterol-independent mechanism in cultured neurons.
Topics: Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Atorvastatin; Cholesterol; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mevalonic Acid; Neurons; Peptide Fragments; Phosphorylation; Pyrroles; Quinolines; Rats | 2013 |
Atorvastatin and pitavastatin reduce oxidative stress and improve IR/LDL-R signals in Alzheimer's disease.
Topics: Adiponectin; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Atorvastatin; Cerebral Cortex; Endothelium, Vascular; Female; Glycation End Products, Advanced; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leptin; Mice; Neurons; Oxidative Stress; Plaque, Amyloid; Pyrroles; Quinolines; Receptor, Insulin; Receptors, LDL | 2013 |
Regulation of multidrug resistance protein 2 (MRP2, ABCC2) expression by statins: involvement of SREBP-mediated gene regulation.
Topics: Animals; Atorvastatin; ATP-Binding Cassette Transporters; Cells, Cultured; Gene Expression Regulation; Hep G2 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Liver X Receptors; Male; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Orphan Nuclear Receptors; Pyrroles; Quinolines; Rats; Rats, Wistar; RNA, Messenger; Sterol Regulatory Element Binding Proteins | 2013 |
Frequency and evolution of thin-capped fibroatheromas in left main coronary artery as assessed by serial virtual histology intravascular ultrasound analysis.
Topics: Aged; Atorvastatin; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Phenotype; Plaque, Atherosclerotic; Pyrroles; Quinolines; Registries; Retrospective Studies; Simvastatin; Ultrasonography, Interventional | 2014 |
Risk of diabetes in patients treated with HMG-CoA reductase inhibitors.
Topics: Aged; Atorvastatin; Diabetes Mellitus; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Quinolines; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2015 |
[Fasciculations, cramps, and statins].
Topics: Atorvastatin; Drug Substitution; Electromyography; Fasciculation; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Leg; Middle Aged; Muscle Cramp; Phytosterols; Quinolines; Rosuvastatin Calcium; Toes | 2015 |
Different effects of statins on induction of diabetes mellitus: an experimental study.
Topics: Atorvastatin; Cell Cycle; Cell Survival; Cells, Cultured; Diabetes Mellitus; Dose-Response Relationship, Drug; Glucose; Humans; Insulin; Insulin Resistance; Insulin-Secreting Cells; Muscle, Skeletal; Pravastatin; Quinolines; Rosuvastatin Calcium; Signal Transduction; Structure-Activity Relationship | 2015 |
[JAPAN-ACS (Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome)].
Topics: Acute Coronary Syndrome; Atorvastatin; Evaluation Studies as Topic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Prospective Studies; Quinolines | 2016 |
Physiologically Based Pharmacokinetic (PBPK) Modeling of Pitavastatin and Atorvastatin to Predict Drug-Drug Interactions (DDIs).
Topics: Atorvastatin; Computer Simulation; Drug Interactions; Humans; Liver-Specific Organic Anion Transporter 1; Models, Biological; Polymorphism, Genetic; Predictive Value of Tests; Quinolines | 2017 |
Statins Reduce Lipopolysaccharide-Induced Cytokine and Inflammatory Mediator Release in an In Vitro Model of Microglial-Like Cells.
Topics: Anti-Inflammatory Agents; Antioxidants; Atorvastatin; Cell Proliferation; Chronic Disease; Dinoprostone; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Inflammation; Interleukin-1beta; Lipids; Lipopolysaccharides; Microglia; Monocytes; Nitric Oxide; Pravastatin; Quinolines; Reactive Oxygen Species; Rosuvastatin Calcium; Simvastatin; THP-1 Cells; Tumor Necrosis Factor-alpha | 2017 |
The differences in the incidence of diabetes mellitus and prediabetes according to the type of HMG-CoA reductase inhibitors prescribed in Korean patients.
Topics: Aged; Atorvastatin; Blood Glucose; Diabetes Mellitus; Disease Progression; Electronic Health Records; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Incidence; Male; Middle Aged; Prediabetic State; Quinolines; Republic of Korea; Retrospective Studies | 2017 |
Explaining Ethnic Variability of Transporter Substrate Pharmacokinetics in Healthy Asian and Caucasian Subjects with Allele Frequencies of OATP1B1 and BCRP: A Mechanistic Modeling Analysis.
Topics: Asian People; Atorvastatin; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carbamates; Computer Simulation; Gene Frequency; Genotype; Healthy Volunteers; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Liver-Specific Organic Anion Transporter 1; Models, Biological; Neoplasm Proteins; Pharmacogenomic Variants; Phenotype; Piperidines; Pravastatin; Quinolines; Rosuvastatin Calcium; White People | 2018 |
Effect of Pitavastatin Compared with Atorvastatin andRosuvastatin on New-Onset Diabetes Mellitus in PatientsWith Acute Myocardial Infarction.
Topics: Atorvastatin; Biomarkers; Diabetes Mellitus; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Quinolines; Registries; Republic of Korea; Risk Factors; Rosuvastatin Calcium | 2018 |
Prediabetes with Hypertension and Dyslipidemia: Are They Triad of Future Cardiovascular Risk?
Topics: Atorvastatin; Cardiovascular Diseases; China; Dyslipidemias; Glucose; Glycated Hemoglobin; Humans; Hypertension; Prediabetic State; Quinolines; Risk Factors | 2019 |
The Presence of a Transporter-Induced Protein Binding Shift: A New Explanation for Protein-Facilitated Uptake and Improvement for In Vitro-In Vivo Extrapolation.
Topics: Animals; Atorvastatin; Biological Transport; Cells, Cultured; Hepatocytes; Kinetics; Liver; Membrane Transport Proteins; Metabolic Clearance Rate; Organic Anion Transporters; Pravastatin; Protein Binding; Quinolines; Rats; Rosuvastatin Calcium | 2019 |
Response Letter to Letter by Venu Jonnalagadda.
Topics: Atorvastatin; China; Dyslipidemias; Glucose; Glycated Hemoglobin; Humans; Hypertension; Prediabetic State; Quinolines | 2019 |
Assessment of therapeutic effects of statin on cardiac sympathetic nerve activity after reperfusion therapy in patients with first ST-segment elevation myocardial infarction and normal low-density lipoprotein cholesterol.
Topics: 3-Iodobenzylguanidine; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Cholesterol, LDL; Echocardiography; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Peptide Fragments; Procollagen; Quinolines; Radiopharmaceuticals; Retrospective Studies; Rosuvastatin Calcium; ST Elevation Myocardial Infarction; Stroke Volume; Sympathetic Nervous System; Treatment Outcome | 2021 |
Primary Prevention of Cardiocerebrovascular Diseases and Related Deaths According to Statin Type.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cerebrovascular Disorders; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Primary Prevention; Pyrroles; Quinolines; Retrospective Studies; Rosuvastatin Calcium; Simvastatin | 2020 |
Pitavastatin versus Atorvastatin: Potential Differences in their Effects on Serum Lipoprotein Lipase and Cardiovascular Disease.
Topics: Atorvastatin; Cardiovascular Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoprotein Lipase; Pyrroles; Quinolines | 2022 |
Pleiotropic effects of pitavastatin: a pilot study using the saphenous vein endothelial cell model of endothelial injury and prevention of atherosclerosis.
Topics: Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Cytokines; Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Pilot Projects; Quinolines; Saphenous Vein; Tumor Necrosis Factor-alpha | 2022 |